Nearly 40% of FDA Advisory Meetings Over 20 Years Included Patient Reps Tied to Pharma-Funded Groups
Analysis of two decades of FDA advisory meetings reveals widespread undisclosed financial ties between patient representatives and pharma-funded advocacy groups. These conflicts, absent from scientific member rules, raise integrity concerns for regulatory decisions. Stronger disclosure policies are required to protect public safety.
Regulatory reform will require updated guidance mandating disclosure of group-level funding and independent audits of representative affiliations. Without these steps, recurring conflicts could erode trust in approvals for high-stakes therapies. The next study needed is a longitudinal analysis linking specific undisclosed ties to voting records and post-market safety signals.
VITALIS: FDA will issue revised patient representative conflict guidance by Q3 2027 requiring group-level funding disclosure, or the rate of undisclosed ties will remain above 35% in subsequent audits.
Sources (3)
- [1]Primary Source(https://www.healthaffairsscholar.org/doi/10.1093/haschl/qyad123)
- [2]Supporting Source(https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2678451)
- [3]Supporting Source(https://www.gao.gov/products/gao-22-104308)